In a cohort of 62 HER2-positive breast cancer patients from a clinical trial, higher CCND1 gene copy number was significantly associated with reduced rates of achieving a pathological complete response to neoadjuvant chemotherapy plus trastuzumab [16]. The gene discussed is ERBB2; the disease is breast cancer.